Dec 31, 2025 04:37PM Femasys (FEMY) files for 68.42M share offering by selling stockholders

Dec 23, 2025 04:11PM Femasys files prospectus to sell up to $9.8 million in shares

Dec 18, 2025 09:15AM Femasys receives FDA clearance for next-generation FemVue device

Nov 25, 2025 09:15AM PharmaCyte Biotech sells Femasys stake, boosts cash to $20 million

Nov 20, 2025 01:06AM Laidlaw Starts Femasys Inc. (FEMY) at Buy

Oct 22, 2025 09:00AM Femasys begins post-market study for FemBloc birth control in Europe

Sep 22, 2025 09:01AM Femasys partners with Medical Electronic Systems for sperm analysis kit

Sep 2, 2025 09:01AM Femasys closes $8 million financing round for product commercialization

Aug 20, 2025 09:01AM Femasys receives UK regulatory approval for FemBloc birth control device

Aug 20, 2025 06:05AM Femasys (FEMY) Files for 11.43M Share Offering

Aug 11, 2025 06:38AM Femasys Inc. (FEMY) Reports In-Line Q2 EPS

Aug 6, 2025 09:00AM Femasys receives first European order for FemBloc contraceptive device

Jun 26, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Femasys Inc. (FEMY)

Jun 25, 2025 09:00AM Femasys (FEMY) Announces European Approval of FemBloc

Jun 17, 2025 09:01AM Femasys (FEMY) Names New Chief Commercial Officer to Drive Execution and Global Growth

May 30, 2025 08:00AM Femasys (FEMY) Prices $4.5M Offering at $0.85/sh

May 29, 2025 04:23PM Femasys (FEMY) Announces Proposed Share Offering, Concurrent Private Placement

May 13, 2025 04:11PM Femasys Inc. (FEMY) PT Lowered to $6 at Jones Trading

May 9, 2025 07:14AM Femasys Inc. (FEMY) Misses Q1 EPS by 4c

May 9, 2025 07:03AM Femasys Inc. (FEMY) PT Lowered to $12 at H.C. Wainwright

Mar 28, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Femasys Inc. (FEMY)

Mar 20, 2025 06:38AM Femasys Inc. (FEMY) PT Raised to $15 at H.C. Wainwright

Mar 14, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Femasys Inc. (FEMY)

Mar 13, 2025 08:33AM Femasys (FEMY) nnounces FemBloc Delivery System Approval in Europe

Feb 25, 2025 09:22AM Femasys (FEMY) Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Feb 11, 2025 09:00AM Femasys (FEMY) Announces UK Regulatory Approvals for FemaSeed for Female Infertility Treatment and Two Diagnostic Devices

Feb 4, 2025 09:00AM Femasys (FEMY) Announces Israeli Regulatory Approvals for FemaSeed

Jan 30, 2025 08:31AM Femasys (FEMY) Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Jan 16, 2025 08:32AM Femasys (FEMY) Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Dec 4, 2024 06:50AM H.C. Wainwright Reiterates Buy Rating on Femasys Inc. (FEMY)

Nov 26, 2024 08:32AM Femasys (FEMY) Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Nov 13, 2024 01:37AM Femasys Inc. (FEMY) Misses Q3 EPS by 4c

Nov 1, 2024 08:32AM Femasys (FEMY) Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Sep 12, 2024 07:50AM H.C. Wainwright Reiterates Buy Rating on Femasys Inc. (FEMY)

Sep 9, 2024 08:33AM Femasys (FEMY) Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Aug 29, 2024 08:35AM Femasys (FEMY) Announces CE Mark and Canadian Approval for FemVue MINI, a Fallopian Tube Assessment Solution

Aug 19, 2024 08:30AM Femasys Inc. at August 20th Virtual Investor Summit Microcap Event

Aug 8, 2024 12:43PM Femasys Inc. (FEMY) PT Lowered to $12 at H.C. Wainwright